Eric C. Peterson, Ph.D.
Phone: (501) 686-7335
Fax: (501) 686-5510
University of Arkansas, 2002
The overall goal of our research is to develop new antibody-based medications to treat chronic and acute methamphetamine (METH) abuse. We are currently accomplishing this goal through two projects in the laboratory. In the first project we are combining antibody therapy and nanotechnology to generate an adaptable range of anti-METH medications (dendribodies) that will have applicability to important therapeutic treatment (e.g., a short-acting medication for overdose and a long-acting, low volume of distribution medication needed for chronic treatment of addiction). These studies will provide the first detailed information on the necessary design features and molecular principles required to create an advanced new generation of novel pharmacokinetic antagonists for the treatment of drug abuse.
In a second project, we are utilizing adeno-associated virus (AAV) particles to deliver genes encoding high-affinity anti-METH antibody fragments discovered by our research team. We envision that AAV-mediated gene transfer could be used to persistently deliver these purposely designed single chain variable fragment (scFv) antibodies, which have precise specificity and high affinity for METH. By the end of these studies, we will know if gene therapy can safely deliver sustained doses of antibody medications sufficient to significantly reduce METH pharmacological effects.
Recent Research Support
NIH/NIDA R01 DA036600 (PI) (07/01/14 – 06/30/18)
“Gene therapy for the treatment of methamphetamine abuse”
R01 DA039195-01 NIH (Co-I) (04/15/15 – 03/31/19)
“Pharmacology and Therapy for MDPV and alpha-PVP Like Drugs of Abuse”
R21 DA041822-01 (Co-I) (07/01/16 – 06/30/18)
Technology for identification of epiproteomes in tissue samples
NIH/NIDA R01 DA026423 (04/01/09 – 03/31/13)
“Antibody-nanoparticle conjugates for the treatment of methamphetamine abuse”
NIH/NIDA NRSA Postdoctoral Fellowship F32 DA018039 (2004 – 2007)
“Single Chain Antibody Medications for(+)METH Abuse”
Reichard E, Nanaware-Kharade N, Gonzalez GA, Thakkar S, Owens SM, Peterson EC. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharmaceutical Research. 2016; Epub (PMID: 27620175).
Peterson EC, Ewing LE. Nanomedicine: Going small to beat the high. News and Views, Nat Nanotechnol. 11(7):580–581, 2016 (PMID: 26974956).
Nanaware-Kharade NS, Thakkar S, Gonzalez III GA, Peterson EC. A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. Sci Rep. 5:12060, 2015 (PMID: 26159352).
Peterson EC, Hambuchen MD, Tawney RL, Gunnell MG, Cowell JL, Lay J, Blough BE, Carroll FI, Owens SM. Simple radiometric method for accurately quantitating epitope densities of hapten-protein conjugates with sulfhydryl linkages. Bioconjugate Chem. 25(12):2112-2115, 2014 (PMID:25426820).
Shakkar S, Nanaware-Kharade N, Celikel R, Peterson EC, Varughese KI. (2014) Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering. Sci Rep. 14:4:3673, 2014 (PMID: 24419156).
Peterson EC, WB Gentry, SM Owens. (2014) Customizing Monoclonal Antibodies for the Treatment of Methamphetamine Abuse: Current and Future Applications. Adv Pharmacol. 69:107-27, 2014 (PMID: 24484976).
Peterson EC, Celikel R, Gokulan K, Varughese KI. Structure of a therapeutic single chain antibody fragment: oligomerization and binding of metabolites. PLoS One. 5;8(12):e82690, 2013 (PMID: 24349338).
Nanaware-Kharade N, Gonzalez GA III, Lay JO Jr, Hendrickson HP, Peterson EC. (2012) Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization Bioconj Chem. 19;23(9):1864-72, 2012 (PMID: 22873701).
Dekeyser JG, Laurenzana EM, Peterson EC, Chen T, Omiecinski CJ. Selective phthalate activation of naturally occurring human constitutive androstane receptor splice variants and the pregnane X receptor. Toxicol Sci. 120(2):381-91, 2011 (PMID: 21227907). Selected as paper of the year by the Society of Toxicology
Carroll FI, Blough BE, Pidaparthi RR, Abraham P, Gong PK, Deng L, Huang X, Gunnell M, Lay JO, Peterson EC, Owens SM. (2011). Synthesis of mercapto-(+)- methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem. 54(14):5221-8, 2011 (PMID: 21682289).
Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets. 10: 892-898, 2011 (PMID: 22229314).